Shares of German biotechnology firm CureVac BV soared 175% in their Nasdaq debut on Friday, marking the first stock market listing of a company developing a potential vaccine to combat the coronavirus.
The stock opened at $44 per share, up from the initial public offering (IPO) price of $16 per share.
CureVac, backed by Microsoft Corp founder and billionaire Bill Gates, sold 13.33 million shares at $16 apiece, the top end of its indicated price range of between $14 and $16 per share.
All feeds
